Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded by Guggenheim to Strong-Buy Rating

Guggenheim upgraded shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) to a strong-buy rating in a report issued on Monday,Zacks.com reports.

Eloxx Pharmaceuticals Trading Down 2.9%

Shares of Eloxx Pharmaceuticals stock opened at $11.65 on Monday. The stock has a market cap of $8.02 million, a price-to-earnings ratio of -0.76 and a beta of -1,891.27. Eloxx Pharmaceuticals has a twelve month low of $11.61 and a twelve month high of $17.50. The company has a 50-day simple moving average of $17.35.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.